Internat Application No PCT/US2005/006108

A. CLASSI IPC 7	FICATION OF SUBJECT MATTER A61K48/00 A61K38/17 A61P35/0	0				
·						
	According to International Patent Classification (IPC) or to both national classification and IPC					
	SEARCHED cumentation searched (classification system followed by classification	on symbols)				
IPC 7 C12N A61K						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched						
Electronic d	ata base consulted during the International search (name of data bas	se and, where practical, search terms used	1)			
EPO-Internal, BIOSIS, WPI Data, PAJ, EMBASE						
C. DOCUMI	ENTS CONSIDERED TO BE RELEVANT	\\	·			
Category °	Citation of document, with indication, where appropriate, of the reta	evant passages	Relevant to daim No.			
X	NEMUNAITIS J ET AL: "Adenovirus-mediated 1-30 p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer"		1-30			
•	JOURNAL OF CLINICAL ONCOLOGY, vol. 18, no. 3, February 2000 (20 pages 609-622, XP002331130 ISSN: 0732-183X					
	page 610, left-hand column, paragraph 5 - right-hand column, paragraph 1 page 611, left-hand column, paragraph 2 page 612, right-hand column, paragraph 5 page 609					
	abstract 		~.			
		-/				
,						
			·			
Further documents are listed in the continuation of box C.  Patent family members are listed in annex.						
° Special ca	tegories of cited documents:	*T* later document published after the inte	emational filing date			
"A" document defining the general state of the art which is not considered to be of particular relevance or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention			eory underlying the			
*E* earlier document but published on or after the international filing date  *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to						
"L° document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or "Involve an inventive step when the document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed inventive step when the document is taken alone cannot be considered to involve an inventive step when the document is taken alone cannot be considered to involve an inventive step when the document is taken alone cannot be considered to involve an inventive step when the document is taken alone cannot be considered to involve an inventive step when the document is taken alone cannot be considered to involve an inventive step when the document is taken alone cannot be considered to involve an inventive step when the document is taken alone cannot be considered to involve an inventive step when the document is taken alone						
other means  "P" document published prior to the international filing date but later than the priority date claimed  "B" document member of the same patent family			us to a person skilled			
Date of the	actual completion of the international search	Date of mailing of the international sea	urch report			
22 June 2005		04/08/2005				
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2		Authorized officer				
NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Sitch, W				

15

Internation No PCT/US2005/006108

	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Category °	Chanon of document, with indication, where appropriate, of the relevant passages	Heievalli to Claim No.
X	BULLER RICHARD E ET AL: "Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500" CANCER GENE THERAPY, vol. 9, no. 7, July 2002 (2002-07), pages 567-572, XP002331131 ISSN: 0929-1903 page 568, left-hand column, paragraph 1 page 569, left-hand column, paragraph 1	1-30
<b>X</b> .	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1997, PIROLLO KATHLEEN F ET AL: "P53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapy" XP002331134 Database accession no. PREV199799548911 abstract & ONCOGENE, vol. 14, no. 14, 1997, pages 1735-1746, ISSN: 0950-9232	1-35
<b>X</b>	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1997, CHANG ESTHER H ET AL: "Restoration of the G-1 checkpoint and the apoptotic pathway mediated by wild-type p53 sensitizes squamous cell carcinoma of the head and neck to radiotherapy" XP002331135 Database accession no. PREV199799596956 abstract & ARCHIVES OF OTOLARYNGOLOGY HEAD AND NECK SURGERY, vol. 123, no. 5, 1997, pages 507-512, ISSN: 0886-4470	1-35

Internal Application No
PCT/US2005/006108

A 15		PC17 U32UU37 UU01U8
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GURNANI MAYA ET AL: "Adenovirus-mediated p53 gene therapy has greater efficacy when combined with chemotherapy against human head and neck, ovarian, prostate, and breast cancer"  CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol. 44, no. 2, August 1999 (1999-08), pages 143-151, XP002331132  ISSN: 0344-5704 page 143 abstract page 144, right-hand column, paragraph 1 page 145, right-hand column, paragraph 4 page 147, right-hand column, paragraph 4 page 148, right-hand column, paragraph 1 page 149	1-35
X	NIELSEN L L ET AL: "ADENOVIRUS-MEDIATED P53 GENE THERAPY AND PACLITAXEL HAVE SYNERGISTIC EFFICACY IN MODELS OF HUMAN HEAD AND NECK, OVARIAN, PROSTATE AND BREAST CANCER" CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 4, no. 4, April 1998 (1998-04), pages 835-846, XP002331133 ISSN: 1078-0432 page 835 abstract page 837, left-hand column, last paragraph - right-hand column, paragraph 1 page 843; figures 6,7	1-35
X	ALEXANDER W A ET AL: "Tumor-targeted sensitization to chemotherapy by systemically delivered ligand mediated wtp53 gene therapy" PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING, vol. 40, March 1999 (1999-03), page 596, XP001206623 & 90TH ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH; PHILADELPHIA, PENNSYLVANIA, USA; APRIL 10-14, 1999 ISSN: 0197-016X abstract #3930	1-35
	•	•

International application No. PCT/US2005/006108

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)				
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:				
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:				
Although claims 1-30 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.				
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:				
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Fule 6.4(a).				
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)				
This international Searching Authority found multiple inventions in this international application, as follows:				
1. As all required additional search fees were timely paid by the applicant, this international Search Report covers all searchable claims.				
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.				
3. As only some of the required additional search fees were timely paid by the applicant, this international Search Report covers only those claims for which fees were paid, specifically claims Nos.:				
4. No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:				
Remark on Protest  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.				